Open Access

Neuroprotective effects of CysLTR antagonist on Streptococcus pneumoniae‑induced meningitis in rats

  • Authors:
    • Shuying Yu
    • Xiaojin Chen
    • Xiaoyu Li
    • Jun Yan
    • Yingying Jiang
  • View Affiliations

  • Published online on: May 13, 2022     https://doi.org/10.3892/etm.2022.11370
  • Article Number: 443
  • Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cysteinyl leukotrienes (CysLTs) modulate central nervous system inflammatory responses via their receptors, CysLT1R and CysLT2R. It has been demonstrated that CysLTR participates in the infection process of Streptococcus pneumoniae (SP)‑induced meningitis. In the present study, the effects and possible underlying mechanisms of CysLTR antagonists (pranlukast and HAMI 3379) on SP meningitis were further determined. SP meningitis was induced by intracerebroventricular injection of serotype III SP in Sprague‑Dawley rats which were administrated intraperitoneally with 0.1 mg/kg antagonists. The clinical disease status of rats was evaluated by body weight and behavioral changes with neurological scoring. Survival neuron density, activated microglial and astrocytes were assessed by Nissl staining and immunohistochemical staining. The expression levels of inflammatory cytokines and NLRP3 inflammasome were detected by reverse transcription‑quantitative PCR and western blotting, respectively. Pranlukast and HAMI 3379 treatment markedly alleviated the clinical disease status, which was manifested by improving body weight loss and neurological deficit. Furthermore, pranlukast and HAMI 3379 treatment ameliorated neuronal injury and inhibited microgliosis and astrogliosis. In addition, significant downregulation of inflammatory cytokines and NLRP3 expression was observed in pranlukast and HAMI 3379‑treated rats. These in vivo findings indicated the neuroprotective effects of CysLTR antagonists against experimental SP‑induced meningitis, and the mechanism of anti‑inflammatory effects may partly be by inhibiting NLRP3 inflammasome overactivation.
View Figures
View References

Related Articles

Journal Cover

July-2022
Volume 24 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yu S, Chen X, Li X, Yan J and Jiang Y: Neuroprotective effects of CysLTR antagonist on <em>Streptococcus pneumoniae</em>‑induced meningitis in rats. Exp Ther Med 24: 443, 2022
APA
Yu, S., Chen, X., Li, X., Yan, J., & Jiang, Y. (2022). Neuroprotective effects of CysLTR antagonist on <em>Streptococcus pneumoniae</em>‑induced meningitis in rats. Experimental and Therapeutic Medicine, 24, 443. https://doi.org/10.3892/etm.2022.11370
MLA
Yu, S., Chen, X., Li, X., Yan, J., Jiang, Y."Neuroprotective effects of CysLTR antagonist on <em>Streptococcus pneumoniae</em>‑induced meningitis in rats". Experimental and Therapeutic Medicine 24.1 (2022): 443.
Chicago
Yu, S., Chen, X., Li, X., Yan, J., Jiang, Y."Neuroprotective effects of CysLTR antagonist on <em>Streptococcus pneumoniae</em>‑induced meningitis in rats". Experimental and Therapeutic Medicine 24, no. 1 (2022): 443. https://doi.org/10.3892/etm.2022.11370